Clinical Trial News and Research

RSS

Research looks at UVB therapy for psoriasis

Ultraviolet light is a proven treatment for psoriasis, one of humanity's oldest known diseases.

29 Apr 2009

New cancer centre launched in Southampton

Southampton joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

29 Apr 2009

Study predicts dramatic growth in cancer rates among US elderly, minorities

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45 percent, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from The University of Texas M. D. Anderson Cancer Center.

29 Apr 2009

Glutamate identified as predictor of disease progression in multiple sclerosis

UCSF researchers have identified a correlation between higher levels of glutamate, which occurs naturally in the brain as a byproduct of metabolism, and greater disease burden in multiple sclerosis patients.

29 Apr 2009

Boots OTC anti-aging cosmetic shown to reduce wrinkles

A product sold over the counter (OTC) in chemists across Britain has been shown to reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight.

29 Apr 2009

Wyeth's Conbriza (bazedoxifene) approved in Europe for postmenopausal osteoporosis

Wyeth Pharmaceuticals has announced that the European Commission has granted marketing authorization for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Autoantibodies may be created in response to bacterial DNA

Autoimmune diseases have long been regarded as illnesses in which the immune system creates autoantibodies to attack the body itself. But today, researchers at the California non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies observed in autoimmune disease actually result from alteration of human genes and gene products by hidden bacteria.

27 Apr 2009

Nanosensor arrays ''sniff out" cancer

In 2006 researchers established that dogs could detect cancer by sniffing the exhaled breath of cancer patients. Now, using nanoscale arrays of detectors, two groups of investigators have shown that a compact mechanical device also can sniff out lung cancer in humans.

27 Apr 2009

New diagnostic technique found for most common bladder tumors

Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial.

26 Apr 2009

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Pharmasset, Inc. and Roche have announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic hepatitis C (HCV).

26 Apr 2009

Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence

The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less.

26 Apr 2009

New drug restricts the growth of neuroblastoma

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a new drug that restricts the growth of neuroblastoma, a childhood brain cancer.

23 Apr 2009

Proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C

The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

23 Apr 2009

In-body stem cell therapy has enormous potential for bone injuries

Rarely will physicians use the word "miraculous" when discussing patient recoveries. But that's the very phrase orthopaedic physicians and scientists are using in upstate New York to describe their emerging stem cell research that could have a profound impact on the treatment of bone injuries. Results from preliminary work being released today, patients confined to wheelchairs were able to walk or live independently again because their broken bones finally healed.

23 Apr 2009

Trial of unique malaria vaccine candidate to begin

In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial - the first tests in adult volunteers - of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria's approach deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.

23 Apr 2009

Link found between vitamin D insufficiency and asthma severity

Serum levels of vitamin D in more than 600 Costa Rican children were inversely linked to several indicators of allergy and asthma severity, including hospitalizations for asthma, use of inhaled steroids and total IgE levels, according to a study that will appear in the first issue for May of the American Journal of Respiratory and Critical Care Medicine.

23 Apr 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Hormone therapy may lower colorectal cancer risk in women

In a large study, a national team of researchers led by Mayo Clinic scientists observed that self-reported use of hormone therapy was associated with a significantly lower colorectal cancer risk.

22 Apr 2009

New applications for proton pump inhibitors

In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

22 Apr 2009